A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratorios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane 0,02mg + 0,075mg (Schering Do Brasil Quimica E Farmaceutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2011
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Feb 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 18 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2010 New trial record